UNITED THERAPEUTICS Corp
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B |
| Gross profit | $2.8B | $2.6B | $2.1B | $1.8B | $1.6B |
| Operating income | $1.5B | $1.4B | $1.2B | $979.7M | $555.9M |
| Cost of revenue | $384.4M | $309.7M | $257.5M | $151.6M | $122.5M |
| Cash from operations | $1.6B | $1.3B | $978.0M | $802.5M | $598.2M |
| Capital expenditure | $520.5M | $246.5M | $230.4M | $138.8M | $120.8M |
| Free cash flow | $1.0B | $1.1B | $747.6M | $663.7M | $477.4M |
| Share repurchases | $1.0B | $1.0B | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $7.9B | $7.4B | $7.2B | $6.0B | $5.2B |
| Total liabilities | $783.8M | $920.0M | $1.2B | $1.2B | $1.2B |
Shares outstanding 42.4M · Free float 18.7%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.